Taipei, Taiwan, 24 September 2025 — Lotus Pharmaceutical (1795:TT, “Lotus” or “the Company”) today announced it has entered into a definitive agreement to acquire 100% equity interest in New Alvogen Group Holdings, Inc (“NAGH”), which owns Alvogen US, a privately held, fully integrated pharmaceutical company based in New Jersey, US.
This acquisition represents a pivotal milestone in Lotus’ proven growth strategy, elevating the Company into the global Top 20 specialty pharmaceutical companies with pro forma combined revenues and EBITDA doubling after closing. The deal adds a complementary pipeline which brings the combined pipeline to nearly 100 products, strengthens Lotus’ commercial capabilities with a dedicated U.S. salesforce, and provides access to a US manufacturing site with an exemplary FDA track record.
The transaction also combines two end-to-end platforms, giving Lotus access to U.S. R&D, manufacturing and commercial capabilities alongside our established strengths in Asia. This creates a stronger foundation to bring specialty products to market globally, while also providing Lotus direct entry into the world’s largest pharmaceutical market with an established platform for future growth.
Leadership Comments
“This landmark acquisition marks a transformative step for Lotus,” said Petar Vazharov, Chief Executive Officer of Lotus Pharmaceutical. “For more than ten years, Lotus and Alvogen US have worked side by side, building trust and delivering results. This long partnership gives us the confidence that integration will be seamless and that together we can create a stronger platform for future growth.”
Robert Wessman, Chairman of Alvogen US and Lotus, added: “We are excited to combine Alvogen US with Lotus Pharmaceutical. This acquisition represents a natural evolution of our long-standing partnership and provides our specialty portfolio and dedicated team with a broader platform for growth and impact. Importantly, this deal is also a testament to Lotus’ proven strategy — solidifying our presence in core markets in APAC and US, scaling new opportunities through B2B and M&A, and bolstering our specialty pipeline. With this consistent vision, we will continue building a sustainable growth path and delivering value for patients and stakeholders globally.”
The transaction implies an enterprise value of approximately up to US$2 billion. The structure includes a mix of cash, preferred shares, and contingent earnout consideration linked to future performance. Closing is subject to customary regulatory approvals.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.
About Alvogen US
Alvogen is a privately-owned company focused on developing, in-licensing, manufacturing and marketing pharmaceutical products. Alvogen is growing its portfolio of complex, high value products including inhalation, long acting injectables, peptides and strategic 505(b)(2) brand products. Presently, Alvogen has over 30 products currently on market and extensive R&D capabilities fueling its growing pipeline. Alvogen maintains dedicated manufacturing facility in the United States, with significant capacity to expand.
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com